Hormonal
Homozgyous carriers of the C allele of the rs1042714 ADRB2 polymorphism experience significantly greater reductions in hip circumference compared to G allele carriers when treated with metformin and diet.
If you are taking metformin alongside a diet for blood sugar issues, your ADRB2 genetics may influence where you lose fat. Those with the CC genotype tend to reduce their hip circumference more significantly than those with the G allele. This suggests that personalized medical advice based on genetics could optimize body shape outcomes.
Carriers of C allele in homozygous state of rs1042714 ADRB2, who took metformin with the diet, demonstrated more decrease in hip circumference (- 5.81 ± 3.00% vs. -2.50 ± 2.7%, p = 0.009)... compared with G allele carriers.
Why this rating
Randomized controlled trial with a small sample size (n=73) and single-center design.
Source
Association of rs7903146 TCF7L2, rs1042714 ADRB2 with the changes in body fat mass in different types of therapy of early carbohydrate metabolism disorders
Ф. В. Валеева et al. · Obesity and metabolism · 2022
DOI 10.14341/omet12807
More from this paper
- Carriers of the T allele of the rs7903146 TCF7L2 polymorphism experience significantly greater reductions in body fat mass compared to CC homozygotes when treated with carbohydrate-restricted diet alone.Moderate
- TCF7L2 and ADRB2 polymorphisms do not significantly influence total body weight changes in patients undergoing diet or metformin therapy.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →